Skip to main content
SpringerLink
Log in

Cannabinoids for Neurological Conditions

  • Chapter
  • First Online:
Cannabis Therapy in Veterinary Medicine

Abstract

Neurologic conditions represent some of the most confusing, challenging, and frustrating cases to treat. Because of this, it is not surprising that many pet owners turn to alternative therapies, including cannabis, to treat their pets. This chapter provides information on the use of cannabinoid compounds for the treatment or management of common neurologic diseases and disorders of dogs and cats.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmed, A., & Wicklund, M. P. (2011). Amyotrophic lateral sclerosis: What role does environment play? Neurologic Clinics, 29, 689–711.

    Article  PubMed  Google Scholar 

  • Ali, S., Scheffer, I. E., & Sadleir, L. G. (2018). Efficacy of cannabinoids in paediatric epilepsy. Developmental Medicine and Child Neurology, 61(1), 13–18. https://doi.org/10.1111/dmcn.14087.

    Article  PubMed  Google Scholar 

  • Anderson, L. L., Low, I. K., Banister, S. D., Mcgregor, I. S., & Arnold, J. C. (2019). Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet syndrome. Journal of Natural Products, 82(11), 3047–3055. https://doi.org/10.1021/acs.jnatprod.9b00600.

    Article  CAS  PubMed  Google Scholar 

  • Ando, R. D., Biro, J., Csolle, C., Ledent, C., & Sperlagh, B. (2012). The inhibitory action of exo- and endocannabinoids on [3H]GABA release are mediated by both CB1 and CB2 receptors in the mouse hippocampus. Neurochemistry International, 60, 145–152.

    Article  CAS  PubMed  Google Scholar 

  • Atwood, B. K., & Mackie, K. (2010). CB2: A cannabinoid receptor with an identity crisis. British Journal of Pharmacology, 160, 467–479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Azkona, G., García-Belenguer, S., Chacón, G., Rosado, B., León, M., & Palacio, J. (2009). Prevalence and risk factors of behavioural changes associated with age-related cognitive impairment in geriatric dogs. Journal of Small Animal Practice, 50, 87–91.

    Article  CAS  Google Scholar 

  • Belardo, C., Iannotta, M., Boccella, S., Rubino, R. C., Ricciardi, F., Infantino, R., et al. (2019). Oral cannabidiol prevents allodynia and neurological dysfunctions in a mouse model of mild traumatic brain injury. Frontiers in Pharmacology, 10. https://doi.org/10.3389/fphar.2019.00352.

  • Biegon, A. (2004). Cannabinoids as neuroprotective agents in traumatic brain injury. Current Pharmaceutical Design, 10(18), 2177–2183.

    Article  CAS  PubMed  Google Scholar 

  • Bisland, L. G., Dick, J. R., Pryce, G., Petrosino, S., Di Marzo, V., Baker, D., et al. (2006). Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB Journal, 20, 1003–1005.

    Article  CAS  Google Scholar 

  • Blennow, K., Hardy, J., & Zetterberg, H. (2012). The neuropathology and neurobiology of traumatic brain injury. Neuron, 76, 886–899.

    Article  CAS  PubMed  Google Scholar 

  • Boggan, W. O., Steele, R. A., & Freedman, D. X. (1973). Delta9-tetrahydrocannabinol effect on audiogenic seizure susceptibility. Psychopharmacologia, 29(2), 101–106. https://doi.org/10.1007/bf00422641.

    Article  CAS  PubMed  Google Scholar 

  • Bolouri, H., & Zetterberg, H. (2015). Animal models for concussion: Molecular and cognitive assessments—relevance to sport and military concussions. In F. H. Kobeissy (Ed.), Brain neurotrauma: Molecular, neuropsychological, and rehabilitation aspects (Chap. 46). Boca Raton, FL: CRC Press/Taylor & Francis. Available from: https://www.ncbi.nlm.nih.gov/books/NBK299196/.

    Google Scholar 

  • Braun, M., Khan, Z., Khan, M., et al. (2018, Feb 6). Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. Brain Behavior and Immunity, 8, 224–237.

    Article  CAS  Google Scholar 

  • Brown, T. M., Brotchie, J. M., & Fitzjohn, S. M. (2003). Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. The Journal of Neuroscience, 23, 11073–11077.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bruijn, L. I., Houseweart, M. K., Kato, S., et al. (1998). Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science, 281(5384), 1851–1854.

    Article  CAS  PubMed  Google Scholar 

  • Cabral, G. A., & Griffin-Thomas, L. (2008). Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocrine, Metabolic & Immune Disorders Drug Targets, 8, 159–172.

    Article  CAS  Google Scholar 

  • Cabral, G. A., & Marciano-Cabral, F. (2005). Cannabinoid receptors in microglia of the central nervous system: Immune functional relevance. Journal of Leukocyte Biology, 78, 1192–1197.

    Article  CAS  PubMed  Google Scholar 

  • Caine, A., Brash, R., De Risio, L., et al. (2018, Dec 19). Magnetic resonance imaging in 30 cats with traumatic brain injury. Journal of Feline Medicine and Surgery.

    Google Scholar 

  • Carter, G. T., Abood, M. E., Aggarwal, S. K., & Weiss, M. D. (2010). Cannabis and amyotrophic lateral sclerosis: Hypothetical and practical applications, and a call for clinical trials. The American Journal of Hospice & Palliative Care, 27, 347–357.

    Article  Google Scholar 

  • Cheung, K. A., Peiris, H., Wallace, G., Holland, O. J., & Mitchell, M. D. (2019). The interplay between the endocannabinoid system, epilepsy and cannabinoids. International Journal of Molecular Sciences, 20(23), 6079. https://doi.org/10.3390/ijms20236079.

    Article  CAS  Google Scholar 

  • Consroe, P. F., & Man, D. P. (1973). Effects of Δ8- and Δ9-tetrahydrocannabinol on experimentally induced seizures. Life Sciences, 13(5), 429–439. https://doi.org/10.1016/0024-3205(73)90034-9.

    Article  CAS  Google Scholar 

  • Correa, F., Mestre, L., Molina-Holgado, E., Arevalo-Martin, A., Docagne, F., Romero, E., et al. (2005). The role of cannabinoid system on immune modulation: Therapeutic implications on CNS inflammation. Mini Reviews in Medicinal Chemistry, 5, 671–675.

    Article  CAS  PubMed  Google Scholar 

  • Croxford, J. L., & Yamamura, T. (2005). Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases. Journal of Neuroimmunology, 166, 3–18.

    Article  CAS  PubMed  Google Scholar 

  • Deabold, K. A., Schwark, W. S., Wolf, L., & Wakshlag, J. J. (2019). Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp neutraceutical in healthy dogs and cats. Animals, 9(10), 832.

    Google Scholar 

  • den Boon, F. S., Chameau, P., Schaafsma-Zhao, Q., van Aken, W., Bari, M., Oddi, S., et al. (2012). Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proceedings of National Academy of Sciences USA, 109, 3534–3539.

    Article  Google Scholar 

  • Dickinson, P. (2014). Advances in diagnostic and treatment modalities for intracranial tumors. Journal of Veterinary Internal Medicine, 28, 1165–1185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dickinson, P., Surace, E., Cambell, M., et al. (2009). Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Veterinary Pathology, 46, 884–892.

    Article  CAS  PubMed  Google Scholar 

  • Dickinson, P., LeCouteur, R., Higgins, R., et al. (2010). Canine spontaneous glioma: A translational model system for convection-enhanced delivery. Neuro-Oncology, 12, 928–940.

    Article  PubMed  PubMed Central  Google Scholar 

  • Dolera, M., Malfassi, L., Bianchi, C., et al. (2018). Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. Veterinary and Comparative Oncology, 16, 90–101.

    Article  CAS  PubMed  Google Scholar 

  • Dumitru, C., Sandalcioglu, I., & Karsak, M. (2018). Cannabinoids in glioblastoma therapy: New applications for old drugs. Frontiers in Molecular Neuroscience, 11(159).

    Google Scholar 

  • Echigo, R., Sugimoto, N., Yachie, A., et al. (2012). Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells. Oncology Reports, 28(4), 1176–1180.

    Article  CAS  PubMed  Google Scholar 

  • Elliott, M., Tuma, R., Amenta, P., et al. (2011, June). Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. Journal of Neurotrauma, 28(6), 973–981.

    Article  PubMed  Google Scholar 

  • Elliott, D. M., Singh, N., Nagarkatti, M., & Nagarkatti, P. S. (2018). Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.01782.

  • Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M., & Leon, A. (2003). Cannabinoids ablate release of TNFalpha in rate microglial cells stimulated with lipopolysaccharide. Glia, 41, 161–168.

    Article  PubMed  Google Scholar 

  • Farrell, D., & Bendo, A. (2018, August). Perioperative management of severe traumatic brain injury: What is new. Current Anesthesiology Reports, 3, 279–289.

    Article  Google Scholar 

  • Fernández-Ruiz, J., González, S., Romero, J., et al. (2005). Cannabinoids in neurodegeneration and neuroprotection. In R. Mechoulam (Ed.), Milestones in drug therapy; Cannabinoids as therapeutics (pp. 79–110).

    Google Scholar 

  • Freundt-Revilla, J., Heinrich, F., Zoerner, A., Gesell, F., Beyerbach, M., Shamir, M., Oevermann, A., Baumgärtner, W., & Tipold, A. (2018). The endocannabinoid system in canine steroid-responsive meningitis-arteritis and intraspinal spirocercosis. PLoS One, 13, e0187197.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • EPIDIOLEX Full Prescribing Information. (2019). Retrieved 2020, from https://www.epidiolex.com/sites/default/files/pdfs/EPIDIOLEX_Full_Prescribing_Information_04_16_2020.pdf

  • Gaston, T. E., & Friedman, D. (2017). Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy & Behavior, 70, 313–318.

    Google Scholar 

  • Gowran, A., Noonan, J., & Campbell, V. A. (2011). The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neuroscience & Therapeutics, 17, 637–644.

    Article  CAS  Google Scholar 

  • Gross, C., Ramirez, D., Dickinson, P., Gustafson, D., & Mcgrath, S. (2020). Cannabidiol induces apoptosis and perturbs mitochondrial function in both human and canine glioma cells. The FASEB Journal, 34(S1), 1. https://doi.org/10.1096/fasebj.2020.34.s1.04176.

    Article  Google Scholar 

  • Grundy, R. I., Rabuffetti, M., & Beltramo, M. (2001). Cannabinoids and neuroprotection. Molecular Neurobiology, 24, 29–51.

    Article  CAS  PubMed  Google Scholar 

  • Hausman, A., & Guerriero, G. (2016). Cannabis sativa: The plant of the thousand and one molecules. Frontiers in Plant Science, 7(19).

    Google Scholar 

  • Hecht, S., & Adams, W. H. (2010, January). MRI of brain disease in veterinary patients. Part 2: Acquired brain disorders. Review. Veterinary Clinics of North America: Small Animal Practice, 40(1), 39–63.

    Article  Google Scholar 

  • Hermanson, D., & Marnett, L. (2011, December). Cannabinoids, endocannabinoids and cancer. Cancer and Metastasis Reviews, 30(3–4), 599–612.

    Article  CAS  PubMed  Google Scholar 

  • Hicks, J., Platt, S., Kent, M., et al. (2017). Canine brain tumours: A model for the human disease? Veterinary and Comparative Oncology, 15, 252–272.

    Article  CAS  PubMed  Google Scholar 

  • Hicks, J., Platt, S., Stewart, G., et al. (2019). Intratumoral temozolomide in spontaneous canine gliomas: Feasibility of a novel therapy using implanted microcylinders. Veterinary Medicine and Science, 5, 5–18.

    Article  CAS  PubMed  Google Scholar 

  • Hill, A., Mercier, M., Hill, T., Glyn, S., Jones, N., Yamasaki, Y., et al. (2012). Cannabidivarin is anticonvulsant in mouse and rat. British Journal of Pharmacology, 167(8), 1629–1642. https://doi.org/10.1111/j.1476-5381.2012.02207.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hinz, B., & Ramer, R. (2019). Review Article: Anti-tumour actions of cannabinoids. British Journal of Pharmacy, 176, 1384–1394. Themed Section: 8th European Workshop on Cannabinoid Research, 2019.

    Article  CAS  Google Scholar 

  • Hockman, C. H., Perrin, R. G., & Kalant, H. (1971). Electroencephalographic and behavioral alterations produced by Delta-1-tetrahydrocannabinol. Science, 172(3986), 968–970.

    Article  CAS  PubMed  Google Scholar 

  • Hu, H., Barker, A., Harcourt-Brown, T., et al. (2015). Systematic review of brain tumor treatment in dogs. Journal of Veterinary Internal Medicine, 29, 1456–1463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnson, D. D., Crichlow, E. C., & Crawford, R. D. (1974). Epileptiform seizures in domestic fowl. IV. The effects of anticonvulsant drugs. Canadian Journal of Physiology and Pharmacology, 52(5), 991–994. https://doi.org/10.1139/y74-130.

    Article  CAS  PubMed  Google Scholar 

  • Johnson, D. D., Mcneill, J. R., Crawford, R. D., & Wilcox, W. C. (1975). Epileptiform seizures in domestic fowl. V. The anticonvulsant activity of Δ9-tetrahydrocannabinol. Canadian Journal of Physiology and Pharmacology, 53(6), 1007–1013. https://doi.org/10.1139/y75-140.

    Article  CAS  PubMed  Google Scholar 

  • Jones, N. A., Hill, A. J., Smith, I., Bevan, S. A., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2010). Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics, 332(2), 569–577.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Joshi, A., Botham, R., Schlein, L., et al. (2017). Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. Oncotarget, 8, 80124–80138.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kato, Y., Nishihara, H., Mohri, H., et al. (2014). Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: Immunohistochemical analysis of 76 cases of low and high-grade meningioma. Brain Tumor Pathology, 31, 23–30.

    Article  CAS  PubMed  Google Scholar 

  • Kitchell, B., & Dervisis. (2010). Pathophysiology and tumor cell growth. In C. Henry & M. Higginbotham (Eds.), Cancer management in small animal practice (pp. 1–9). St. Louis, MI: Saunders Elsevier.

    Google Scholar 

  • Klein, T. W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews. Immunology, 5, 400–411.

    Article  CAS  PubMed  Google Scholar 

  • Kong, W., Li, H., Tuma, R. F., & Ganea, D. (2014). Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS. Cellular Immunology, 287, 1–17.

    Article  CAS  PubMed  Google Scholar 

  • Kostic, D., Carlson, R., Henke, D., et al. (2019, June 17). Evaluation of IL-1β levels in epilepsy and traumatic brain injury in dogs. BMC Neuroscience, 20(1), 29.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kuo, K., Bacek, L., & Taylor, A. (2018, January). Head trauma. Review. Veterinary Clinics of North America: Small Animal Practice, 48(1), 111–128.

    Article  Google Scholar 

  • Labrecque, G., Hallé, S., Berthiaume, A., Morin, G., & Morin, P. J. (1978). Potentiation of the epileptogenic effect of penicillin G by marijuana smoking. Canadian Journal of Physiology and Pharmacology, 56(1), 87–96.

    Article  CAS  PubMed  Google Scholar 

  • Lanciego, J. L., Barroso-Chinea, P., Rico, A. J., Conte-Perales, L., Callen, L., Roda, E., et al. (2011). Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. Journal of Psychopharmacology, 25, 97–104.

    Article  CAS  PubMed  Google Scholar 

  • Liu, Y., McAfee, S., Guley, N., et al. (2017, August 18). Abnormalities in dynamic brain activity caused by mild traumatic brain injury are partially rescued by the cannabinoid type-2 receptor inverse agonist SMM-189. eNeuro, 4(4).

    Google Scholar 

  • Lopez-Rodriguez, A., Mela, V., Acaz-Fonseca, E., et al. (2016, May). CB2 cannabinoid receptor is involved in the anti-inflammatory effects of leptin in a model of traumatic brain injury. Experimental Neurology, 279, 274–282.

    Article  CAS  PubMed  Google Scholar 

  • López-Valero, I., Saiz-Ladera, C., Torres, S., et al. (2017, November). Targeting glioma initiating cells with a combined therapy of cannabinoids and temozolomide. Biochemical Pharmacology, 157, 266–274. Epub September 7, 2018.

    Google Scholar 

  • Maiolini, A., Otten, M., Hewicker-Trautwein, M., Carlson, R., & Tipold, A. (2013). Interleukin-6, vascular endothelial growth factor and transforming growth factor beta 1 in canine steroid responsive meningitis-arteritis. BMC Veterinary Research, 9, 23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Malyshevskaya, O., Aritake, K., Kaushik, M. K., Uchiyama, N., Cherasse, Y., Kikura-Hanajiri, R., & Urade, Y. (2017). Natural (Δ9-THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the cannabinoid CB1 receptor. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-10447-2.

  • Martinez, F. O., & Gordon, S. (2014). The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Reports, 6. https://doi.org/10.12703/p6-13.

  • Mayer, A., Dodd, A., Vermillion, M., et al. (2019, June). A systematic review of large animal models of combined traumatic brain injury and hemorrhagic shock. Neuroscience and Biobehavioral Reviews, 27.

    Google Scholar 

  • McGrath, S., Bartner, L. R., Rao, S., Packer, R. A., & Gustafson, D. L. (2019). Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association, 254(11), 1301–1308.

    Article  CAS  PubMed  Google Scholar 

  • Mechoulam, R. (2016). Cannabis – The Israeli perspective. Review. Journal of Basic Clinical Physiology and Pharmacology, 27(3), 181–187.

    Article  Google Scholar 

  • Mechoulam, R., Panikashvili, D., & Shohami, E. (2002, February). Cannabinoids and brain injury: Therapeutic implications. Trends in Molecular Medicine, 8(2), 58–61.

    Article  CAS  PubMed  Google Scholar 

  • Minghetti, L. (2005). Role of inflammation in neurodegenerative diseases. Current Opinion in Neurology, 18, 315–321.

    Article  CAS  PubMed  Google Scholar 

  • Molina-Holgado, F., Molina-Holgado, E., & Guasa, C. (1998). The endogenous cannabinoid anadamide potentiates interleukin-6 production by astrocytes infected with Theiler’s murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Letters, 433, 139–142.

    Article  CAS  PubMed  Google Scholar 

  • Moreno, E., Cavic, M., Krivokuca, A., et al. (2019, April). The endocannabinoid system as a target in cancer diseases: Are we there yet? Frontiers in Pharmacology, 5(10), 1–23.

    Google Scholar 

  • Moreno-Martet, M., Espejo-Porras, F., Fernandez-Ruiz, J., & de Lago, E. (2014). Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis. CNS Neuroscience & Therapeutics, 20, 809–815.

    Article  CAS  Google Scholar 

  • Murtagh, K., Arrol, L., Goncalves, R., et al. (2015, January 3). Hypothalamic-anterior pituitary hormone deficiencies following traumatic brain injury in dogs. Veterinary Records, 176(1), 20.

    Article  CAS  Google Scholar 

  • Namas, R., Ghuma, A., Hermus, L., et al. (2009). The acute inflammatory response in trauma/hemorrhage and traumatic brain injury: Current state and emerging prospects. Libyan Journal of Medicine, 4, 97–102.

    Article  CAS  Google Scholar 

  • Oddi, S., Scipioni, L., & Maccarrone, M. (2020). Endocannabinoid system and adult neurogenesis: A focused review. Current Opinion in Pharmacology, 50, 25–32. https://doi.org/10.1016/j.coph.2019.11.002.

    Article  CAS  PubMed  Google Scholar 

  • Orihuela, R., Mcpherson, C. A., & Harry, G. J. (2015). Microglial M1/M2 polarization and metabolic states. British Journal of Pharmacology, 173(4), 649–665. https://doi.org/10.1111/bph.13139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Panikashvili, D., Simeonidou, C., Ben-Shabat, S., et al. (2001, October 4). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413(6855), 527–531.

    Article  CAS  PubMed  Google Scholar 

  • Parratt, C., Firth, A., Boag, A., et al. (2018, November). Retrospective characterization of coma and stupor in dogs and cats presenting to a multicenter out-of-hours service (2012-2015): 386 animals. The Journal of Veterinary Emergency and Critical Care, 28(6), 559–565.

    Article  PubMed  Google Scholar 

  • Passmore, M. J. (2008). The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. International Journal of Geriatric Psychiatry, 23, 116–117.

    Article  PubMed  Google Scholar 

  • Pellati, F., Borgonetti, V., Brighenti, V., et al. 2018, December 4. Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. BioMed Research International, 1691428. eCollection, 2018.

    Google Scholar 

  • Perucca, E. (2017). Cannabinoids in the treatment of epilepsy: Hard evidence at last? Journal of Epilepsy Research, 7(2), 61–76. https://doi.org/10.14581/jer.17012.

    Article  PubMed  PubMed Central  Google Scholar 

  • Petersen, G., Moesgaard, B., & Schmid, P. (2005). Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. Journal of Neurochemistry April, 93(2), 299–309.

    Article  CAS  Google Scholar 

  • Piro, J., Suidan, G., Quan, J., et al. (2018, May 14). Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury. Journal of Neuroinflammation, 15(1), 142.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Prpar Mihevc, S., & Majdič, G. (2019). Canine cognitive dysfunction and Alzheimer’s disease – Two facets of the same disease? Frontiers in Neuroscience, 13, 604.

    Article  PubMed  PubMed Central  Google Scholar 

  • Puffenbarger, R. A., Boothe, A. C., & Cabral, G. A. (2000). Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia, 29, 58–69.

    Article  CAS  PubMed  Google Scholar 

  • Rakhit, R., & Chakrabartty, A. (2006). Structure, folding, and misfolding of Cu, Zn superoxide dismutase in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta, 1762(11–12), 1025–1037.

    Article  CAS  PubMed  Google Scholar 

  • Raman, C., McAllister, S. D., Rizvi, G., Patel, S. G., Moore, D. H., & Abood, M. E. (2004). Amyotrophic lateral sclerosis: Delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis, 8, 157–163.

    Google Scholar 

  • Ramer, R., & Hinz, B. (2017, June 12). Cannabinoids as anticancer drugs. Advances in Pharmacology, 80, 397–436, Epub 2017.

    Google Scholar 

  • Ramer, R., Schwarz, R., & Hinz, B. (2019, May 9). Modulation of the endocannabinoid system as potential anticancer strategy. Frontiers in Pharmacology, 10, 430, eCollection.

    Google Scholar 

  • Renton, A. E., Chio, A., & Traynor, B. J. (2014). State of play in amyotrophic lateral sclerosis genetics, 2014. Nature Neuroscience, 17, 17–23.

    Article  CAS  PubMed  Google Scholar 

  • Rikkert, M. O. (2014a). Two phase repeated crossover study with dose escalation on delta(9)-tetrahydrocannabinol (delta-THC). In Behavioural disturbances in dementia. [Online]. Washington, DC: U.S. National Institutes of Health.

    Google Scholar 

  • Rikkert, M. O. (2014b). Efficacy and safety of delta-9-tetrahydrocannabinol. In Behavioral disturbances and pain in dementia. [Online]. Washington, DC: U.S. National Institutes of Health.

    Google Scholar 

  • Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015). Cannabinoids and epilepsy. Neurotherapeutics, 12(4), 747–768. https://doi.org/10.1007/s13311-015-0375-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rossi, S., Bernardi, G., & Centonze, D. (2010). The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Experimental Neurology, 224, 92–102.

    Article  CAS  PubMed  Google Scholar 

  • Russo, E. (2018). Cannabis therapeutics and the future of neurology. Frontiers in Integrative Neuroscience, 12, 51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Salazar, M., Carracedo, A., Salanueva, I. J., Hernandez-Tiera, S., Lorente, M., Egia, A., et al. (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. The Journal of Clinical Investigation, 119, 1359–1372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sanchez, C., Galve-Roperh, I., Rueda, D., & Guzman, M. (1998). Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Molecular Pharmacology, 54, 834–843.

    Article  CAS  PubMed  Google Scholar 

  • Schlein, L., Fadl-Alla, B., & Pondenis, H. (2019, February 25). Immunohistochemical characterization of procaspase-3 overexpression as a druggable target with PAC-1, a procaspase-3 activator, in canine and human brain cancers. Frontiers in Oncology, 9, 96, eCollection.

    Google Scholar 

  • Schwarz, R., Ramer, R., & Hinz, B. (2018, February 1). Targeting the endocannabinoid system as a potential anticancer approach. Drug Metabolism Reviews, 50(1), 26–53, Epub 2018.

    Google Scholar 

  • Sheng, W. S., Hu, S., Min, X., Cabral, G. A., Lokensgard, J. R., & Peterson, P. K. (2005). Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia, 49, 211–219.

    Article  PubMed  Google Scholar 

  • Shoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P., & Prather, P. L. (2007). The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Journal of Neurochemistry, 101, 87–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Snyder, J., Shofer, F., Van Winkle, T., et al. (2016). Canine intracranial primary neoplasia: 173 cases (1986-2003). Journal of Veterinary Internal Medicine, 20, 669–675.

    Google Scholar 

  • Stella, N. (2004). Cannabinoid signaling in glial cells. Glia, 48, 267–277.

    Article  PubMed  Google Scholar 

  • Stella, N. (2010). Cannabinoid and cannabinoid-like receptors in microglial, astrocytes, and astrocytomas. Glia, 58, 1017–1030.

    Article  PubMed  PubMed Central  Google Scholar 

  • Szaflarski, J. P., Hernando, K., Bebin, E. M., Gaston, T. E., Grayson, L. E., Ampah, S. B., & Moreadith, R. (2019). Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy & Behavior, 95, 131–136. https://doi.org/10.1016/j.yebeh.2019.03.042.

    Article  Google Scholar 

  • Szarka, N., Toth, L., Czigler, A., Kellermayer, Z., Ungvari, Z., et al. (2019, June 30). Single mild traumatic brain injury induces persistent disruption of the blood-brain barrier, neuroinflammation and cognitive decline in hypertensive rats. International Journal of Molecular Science, 20(13).

    Google Scholar 

  • Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., et al. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomized, double-blind, placebo-controlled phase 3 trial. The Lancet, 391(10125), 1085–1096.

    Article  CAS  Google Scholar 

  • Uliel-Sibony, S., Hausman-Kedem, M., Fattal-Valevski, A., & Kramer, U. (2020). Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy-does tolerance exist? Brain Development. https://doi.org/10.1016/j.braindev.2020.06.018.

  • van der Stelt, M., & Di Marzo, V. (2005). Cannabinoid receptors and their role in neuroprotection. NeuroMolecular Medicine, 7, 37–50.

    Article  PubMed  Google Scholar 

  • van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310, 329–332.

    Article  PubMed  CAS  Google Scholar 

  • Verkhratsky, A., & Butt, A. (2007). Glial cells and nervous system function: Astrocytes. In Glial neurobiology: A textbook (pp. 95–123). New York: Wiley.

    Chapter  Google Scholar 

  • Wada, J. A., Sato, M., & Corcoran, M. E. (1973). Antiepileptic properties of 9-tetrahydrocannabinol. Experimental Neurology, 39(1), 157–165.

    Article  CAS  PubMed  Google Scholar 

  • Wada, J. A., Wake, A., Sato, M., & Corcoran, M. E. (1975). Antiepileptic and prophylactic effects of tetrahydrocannabinols and amygdaloid kindling cats. Epilepsia, 16(3), 503–510.

    Article  CAS  PubMed  Google Scholar 

  • Waksman, Y., Olson, J. M., Carlisle, S. J., & Cabral, G. A. (1999). The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. The Journal of Pharmacology and Experimental Therapeutics, 288, 1357–1366.

    CAS  PubMed  Google Scholar 

  • Walter, L., Franklin, A., Witting, A., Moller, T., & Stella, N. (2002). Astrocytes in culture produce anadamide and other acylethanolamides. The Journal of Biological Chemistry, 277, 20869–20876.

    Article  CAS  PubMed  Google Scholar 

  • Walther, S., Mahlberg, R., Eichmann, U., & Kunz, D. (2006). Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology, 185, 524–528.

    Article  CAS  PubMed  Google Scholar 

  • Williams, A., Dennahy, I., Bhatti, U., et al. (2019). Mesenchymal stem cell-derived exosomes provide neuroprotection and improve longterm neurologic outcomes in a swine model of traumatic brain injury and hemorrhagic shock. Journal of Neurotrauma, 36, 54–60.

    Article  PubMed  Google Scholar 

  • Witting, A., Weydt, P., Hong, S., Kliot, M., Moller, T., & Sella, N. (2004). Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. Journal of Neurochemistry, 89, 1555–1557.

    Article  CAS  PubMed  Google Scholar 

  • Whalley, B. J., Lin, H., Bell, L., Hill, T., Patel, A., Gray, R. A., Roberts, C. E., Devinsky, O., Bazelot, M., Williams, C. M., & Stephens, G. J. (2018). Species-specific susceptibility to cannabis-induced convulsions. British Journal of Pharmacology, 176(10), 1506–1523.

    Google Scholar 

  • Yu, C.-H., Song, G.-S., Yhee, J.-Y., Kim, J.-H., Im, K.-S., Nho, W.-G., Lee, J.-H., & Sur, J.-H. (2011). Histopathological and immunohistochemical comparison of the brain of human patients with Alzheimer’s disease and the brain of aged dogs with cognitive dysfunction. Journal of Comparative Pathology, 145, 45–58.

    Article  CAS  PubMed  Google Scholar 

  • Zeng, R., Coates, J. R., Johnson, G. C., Hansen, L., Awano, T., Kolicheski, A., Ivansson, E., Perloski, M., Lindblad-Toh, K., O’Brien, D. P., Guo, J., Katz, M. L., & Johnson, G. S. (2014). Breed distribution of SOD1 alleles previously associated with canine degenerative myelopathy. Journal of Veterinary Internal Medicine, 28, 515–521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Department, MedVet Silicon Valley, San Jose, CA, USA

    Baye G. Williamson

  2. Bush Veterinary Neurology Service, Frederick, MD, USA

    Joli Jarboe & Christine Weaver

Authors
  1. Baye G. Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joli Jarboe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Weaver
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Veterinary Cannabinoid Academy, San Jose, CA, USA

    Stephen Cital

  2. VCA Canada Vancouver Animal Wellness Hospital, Vancouver, BC, Canada

    Katherine Kramer

  3. Veterinary Cannabinoid Academy, San Jose, CA, USA

    Liz Hughston

  4. Peak Performance Veterinary Group, Breckenridge, CO, USA

    James S. Gaynor

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Williamson, B.G., Jarboe, J., Weaver, C. (2021). Cannabinoids for Neurological Conditions. In: Cital, S., Kramer, K., Hughston, L., Gaynor, J.S. (eds) Cannabis Therapy in Veterinary Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-68317-7_6

Download citation

Publish with us

Policies and ethics

Search

Navigation